RS62292B1 - 1,2,4]triazolo[1,5-a]piridinil supstituisana jedinjenja indola - Google Patents
1,2,4]triazolo[1,5-a]piridinil supstituisana jedinjenja indolaInfo
- Publication number
- RS62292B1 RS62292B1 RS20211090A RSP20211090A RS62292B1 RS 62292 B1 RS62292 B1 RS 62292B1 RS 20211090 A RS20211090 A RS 20211090A RS P20211090 A RSP20211090 A RS P20211090A RS 62292 B1 RS62292 B1 RS 62292B1
- Authority
- RS
- Serbia
- Prior art keywords
- triazolo
- substituted indole
- indole compounds
- pyridinyl substituted
- pyridinyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201611022328 | 2016-06-29 | ||
| US15/635,055 US10071079B2 (en) | 2016-06-29 | 2017-06-27 | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| EP17737442.8A EP3478682B1 (en) | 2016-06-29 | 2017-06-28 | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| PCT/US2017/039633 WO2018005586A1 (en) | 2016-06-29 | 2017-06-28 | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS62292B1 true RS62292B1 (sr) | 2021-09-30 |
Family
ID=60805851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20211090A RS62292B1 (sr) | 2016-06-29 | 2017-06-28 | 1,2,4]triazolo[1,5-a]piridinil supstituisana jedinjenja indola |
Country Status (31)
| Country | Link |
|---|---|
| US (8) | US10071079B2 (sr) |
| EP (1) | EP3478682B1 (sr) |
| JP (1) | JP6995067B6 (sr) |
| KR (1) | KR102473482B1 (sr) |
| CN (1) | CN109641895B (sr) |
| AR (1) | AR108905A1 (sr) |
| AU (1) | AU2017287902B2 (sr) |
| BR (1) | BR112018077119A2 (sr) |
| CA (1) | CA3029620A1 (sr) |
| CL (1) | CL2018003821A1 (sr) |
| CO (1) | CO2019000686A2 (sr) |
| CY (1) | CY1124514T1 (sr) |
| DK (1) | DK3478682T3 (sr) |
| EA (1) | EA037530B1 (sr) |
| ES (1) | ES2886964T3 (sr) |
| HR (1) | HRP20211261T8 (sr) |
| HU (1) | HUE056091T2 (sr) |
| IL (1) | IL263961B (sr) |
| LT (1) | LT3478682T (sr) |
| MX (1) | MX2018015422A (sr) |
| MY (1) | MY196474A (sr) |
| PE (1) | PE20190324A1 (sr) |
| PL (1) | PL3478682T3 (sr) |
| PT (1) | PT3478682T (sr) |
| RS (1) | RS62292B1 (sr) |
| SG (1) | SG11201811590RA (sr) |
| SI (1) | SI3478682T1 (sr) |
| TW (1) | TWI636053B (sr) |
| UY (1) | UY37310A (sr) |
| WO (1) | WO2018005586A1 (sr) |
| ZA (1) | ZA201900571B (sr) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| AU2017307208B2 (en) | 2016-07-30 | 2021-01-21 | Bristol-Myers Squibb Company | Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors |
| EP3510024B1 (en) | 2016-09-09 | 2021-11-17 | Bristol-Myers Squibb Company | Pyridyl substituted indole compounds |
| BR112019007450A2 (pt) | 2016-10-14 | 2020-07-07 | Precision Biosciences, Inc. | meganucleases modificadas específicas para sequências de reconhecimento no genoma do vírus da hepatite b |
| WO2019028301A1 (en) * | 2017-08-04 | 2019-02-07 | Bristol-Myers Squibb Company | INDOLE COMPOUNDS SUBSTITUTED WITH [1,2,4] TRIAZOLO [4,3-A] PYRIDINYL |
| ES2909401T3 (es) | 2017-08-04 | 2022-05-06 | Bristol Myers Squibb Co | Compuestos de indol sustituidos útiles como inhibidores de TLR7/8/9 |
| WO2019099336A1 (en) * | 2017-11-14 | 2019-05-23 | Bristol-Myers Squibb Company | Substituted indole compounds |
| SG11202005513TA (en) * | 2017-12-15 | 2020-07-29 | Bristol Myers Squibb Co | Substituted indole ether compounds |
| AU2018390543A1 (en) * | 2017-12-19 | 2020-08-06 | Bristol-Myers Squibb Company | 6-azaindole compounds |
| EA202091483A1 (ru) | 2017-12-19 | 2020-10-28 | Бристол-Маерс Сквибб Компани | Амидзамещенные индольные соединения, пригодные в качестве ингибиторов tlr |
| SG11202005696YA (en) * | 2017-12-19 | 2020-07-29 | Bristol Myers Squibb Co | Substituted indole compounds useful as tlr inhibitors |
| WO2019123340A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| SG11202005694RA (en) | 2017-12-20 | 2020-07-29 | Bristol Myers Squibb Co | Amino indole compounds useful as tlr inhibitors |
| SG11202005733QA (en) | 2017-12-20 | 2020-07-29 | Bristol Myers Squibb Co | Diazaindole compounds |
| US11420958B2 (en) | 2017-12-20 | 2022-08-23 | Bristol-Myers Squibb Company | Aryl and heteroaryl substituted indole compounds |
| EP3752505B1 (en) | 2018-02-12 | 2023-01-11 | F. Hoffmann-La Roche AG | Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection |
| CN111788204B (zh) | 2018-02-26 | 2023-05-05 | 吉利德科学公司 | 作为hbv复制抑制剂的取代吡咯嗪化合物 |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| CA3093888A1 (en) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’－環二核苷酸 |
| US11713327B2 (en) | 2018-06-12 | 2023-08-01 | Hoffmann-La Roche Inc. | Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease |
| CN112585134A (zh) * | 2018-06-13 | 2021-03-30 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的吡啶基杂环基化合物 |
| EP3826724B1 (en) | 2018-07-23 | 2022-10-05 | F. Hoffmann-La Roche AG | Novel piperazine compounds for the treatment of autoimmune disease |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| WO2020048583A1 (en) | 2018-09-04 | 2020-03-12 | F. Hoffmann-La Roche Ag | Benzothiazole compounds for the treatment of autoimmune diseases |
| CN112654618A (zh) | 2018-09-06 | 2021-04-13 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的新型环脒化合物 |
| WO2020086505A1 (en) * | 2018-10-24 | 2020-04-30 | Bristol-Myers Squibb Company | Substituted indole dimer compounds |
| US20210403468A1 (en) * | 2018-10-24 | 2021-12-30 | Bristol-Myers Squibb Company | Substituted indole and indazole compounds |
| LT3873903T (lt) | 2018-10-31 | 2024-05-10 | Gilead Sciences, Inc. | Pakeistieji 6-azabenzimidazolo junginiai, kaip hpk1 inhibitoriai |
| CA3116347A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| WO2020178769A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| JP7350872B2 (ja) | 2019-03-07 | 2023-09-26 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | ３’３’－環状ジヌクレオチドおよびそのプロドラッグ |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| JP2022532568A (ja) * | 2019-05-07 | 2022-07-15 | ブリストル－マイヤーズ スクイブ カンパニー | プロドラッグ化合物 |
| WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| CN110146631B (zh) * | 2019-06-25 | 2021-11-12 | 山西康宝生物制品股份有限公司 | 一种药用材料中聚乙二醇单甲醚残留量的检测方法 |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| CN117843811A (zh) | 2019-09-30 | 2024-04-09 | 吉利德科学公司 | Hbv疫苗和治疗hbv的方法 |
| WO2021067657A1 (en) * | 2019-10-04 | 2021-04-08 | Bristol-Myers Squibb Company | Substituted carbazole compounds |
| WO2021113765A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| TW202200161A (zh) | 2020-03-20 | 2022-01-01 | 美商基利科學股份有限公司 | 4’-c-經取代-2-鹵基-2’-去氧腺苷核苷之前藥及其製造與使用方法 |
| JP2023530264A (ja) | 2020-06-11 | 2023-07-14 | ブリストル－マイヤーズ スクイブ カンパニー | 皮膚エリテマトーデスを治療するためにプレドニゾロンまたはヒドロキシクロロキンと組み合わせるｔｌｒ７阻害剤 |
| BR112022025920A2 (pt) | 2020-06-22 | 2023-01-10 | Bristol Myers Squibb Co | Tratamento de artrite reumatoide |
| TW202214632A (zh) * | 2020-07-27 | 2022-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 吲哚稠環類衍生物、其製備方法及其在醫藥上的應用 |
| WO2022111636A1 (zh) | 2020-11-26 | 2022-06-02 | 江苏恒瑞医药股份有限公司 | 稠合三环化合物、其制备方法及其在医药上的应用 |
| IL307203A (en) | 2021-04-16 | 2023-11-01 | Gilead Sciences Inc | THIENOPYRROLE COMPOUNDS |
| JP2024518558A (ja) | 2021-05-13 | 2024-05-01 | ギリアード サイエンシーズ， インコーポレイテッド | ＴＬＲ８調節化合物と抗ＨＢＶ ｓｉＲＮＡ治療薬との組合せ |
| CN113416188B (zh) * | 2021-05-31 | 2022-12-13 | 河南偶联生物科技有限公司 | 一种[1,2,4]***并[1,5-a]吡啶化合物的合成方法 |
| CA3220923A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022298639A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2024015825A1 (en) | 2022-07-13 | 2024-01-18 | Bristol-Myers Squibb Company | Processes for preparing 5-bromo-3,4-dimethylpyridin-2-amine and 6-bromo-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6867200B1 (en) | 1998-12-18 | 2005-03-15 | Axys Pharmaceuticals, Inc. | (Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors |
| EA200600069A1 (ru) | 2003-06-20 | 2006-08-25 | Коли Фармасьютикал Гмбх | Низкомолекулярные антагонисты toll-подобных рецепторов (tlr) |
| WO2006113458A1 (en) * | 2005-04-15 | 2006-10-26 | Bristol-Myers Squibb Company | Heterocyclic inhibitors of protein arginine methyl transferases |
| AU2007234399A1 (en) | 2006-04-04 | 2007-10-11 | Myriad Genetics, Inc. | Compounds for diseases and disorders |
| DE102006033109A1 (de) | 2006-07-18 | 2008-01-31 | Grünenthal GmbH | Substituierte Heteroaryl-Derivate |
| US8027888B2 (en) | 2006-08-31 | 2011-09-27 | Experian Interactive Innovation Center, Llc | Online credit card prescreen systems and methods |
| ATE495743T1 (de) | 2006-12-01 | 2011-02-15 | Galapagos Nv | Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten |
| WO2008152471A1 (en) | 2007-06-12 | 2008-12-18 | Coley Pharmaceutical Group, Inc. | Quinazoline derivative useful as toll-like receptor antagonist |
| WO2009030996A1 (en) | 2007-09-05 | 2009-03-12 | Coley Pharmaceutical Group, Inc. | Triazole compounds as toll-like receptor (tlr) agonists |
| FR2926556B1 (fr) * | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique |
| EP2350032B1 (en) | 2008-09-26 | 2016-05-25 | Eisai R&D Management Co., Ltd. | Benzoxazole compounds and methods of use |
| CA2738929A1 (en) | 2008-10-17 | 2010-04-22 | Boehringer Ingelheim International Gmbh | Heteroaryl substituted indole compounds useful as mmp-13 inhibitors |
| RU2011137419A (ru) | 2009-02-11 | 2013-03-20 | Суновион Фармасьютикалз Инк. | Обратные агонисты и антагонисты гистамина н3 и способы их применения |
| KR20120035183A (ko) | 2009-06-10 | 2012-04-13 | 선오비온 파마슈티컬스 인코포레이티드 | 히스타민 ｈ3 역 작용제 및 길항제, 및 이의 사용 방법 |
| TWI462920B (zh) * | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| EP2453895B1 (en) | 2009-07-16 | 2018-05-23 | Mallinckrodt LLC | (+) - morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof |
| US9241991B2 (en) | 2010-10-21 | 2016-01-26 | The Brigham And Women's Hospital, Inc. | Agents, compositions, and methods for treating pruritus and related skin conditions |
| PL2663555T4 (pl) | 2011-01-12 | 2017-08-31 | Ventirx Pharmaceuticals, Inc. | Podstawione benzoazepiny jako modulatory receptora toll-podobnego |
| PL2663550T4 (pl) | 2011-01-12 | 2017-07-31 | Ventirx Pharmaceuticals, Inc. | Podstawione benzoazepiny jako modulatory receptora toll-podobnego |
| CA2837207A1 (en) | 2011-06-01 | 2012-12-06 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
| RU2606114C2 (ru) | 2011-06-01 | 2017-01-10 | Джейнус Байотерапьютикс, Инк. | Новые модуляторы иммунной системы |
| KR101913619B1 (ko) | 2011-06-09 | 2018-12-28 | 리젠 파마슈티컬스 소시에떼 아노님 | Gpr-119의 조절제로서의 신규한 화합물 |
| WO2013009140A2 (en) | 2011-07-13 | 2013-01-17 | Sk Chemicals Co., Ltd. | 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors |
| CA2850932A1 (en) | 2011-10-04 | 2013-04-11 | Janus Biotherapeutics, Inc. | Novel imidazole quinoline-based immune system modulators |
| TWI619704B (zh) | 2012-05-18 | 2018-04-01 | 大日本住友製藥股份有限公司 | 羧酸化合物 |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| AU2014334554B2 (en) | 2013-10-14 | 2018-12-06 | Eisai R&D Management Co., Ltd. | Selectively substituted quinoline compounds |
| US9643967B2 (en) | 2013-12-13 | 2017-05-09 | Takeda Pharmaceutical Company Limited | Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors |
| EP3398948A3 (en) | 2014-08-22 | 2018-12-05 | Janus Biotherapeutics, Inc. | 2,4,6,7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof |
| US9550778B2 (en) | 2014-10-03 | 2017-01-24 | Vanderbilt University | Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5 |
| EP3334745B1 (en) | 2015-08-13 | 2024-05-15 | Merck Sharp & Dohme LLC | Cyclic di-nucleotide compounds as sting agonists |
| IL263934B2 (en) | 2016-06-29 | 2023-10-01 | Hanmi Pharm Ind Co Ltd | A derivative of glucagon, its conjugate, a preparation containing it and its medical use |
| US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| SG11201811507YA (en) | 2016-06-29 | 2019-01-30 | Kezar Life Sciences | Crystalline salts of peptide epoxyketone immunoproteasome inhibitor |
| AU2017307208B2 (en) | 2016-07-30 | 2021-01-21 | Bristol-Myers Squibb Company | Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors |
| EP3510024B1 (en) | 2016-09-09 | 2021-11-17 | Bristol-Myers Squibb Company | Pyridyl substituted indole compounds |
| ES2909401T3 (es) | 2017-08-04 | 2022-05-06 | Bristol Myers Squibb Co | Compuestos de indol sustituidos útiles como inhibidores de TLR7/8/9 |
| WO2019028301A1 (en) | 2017-08-04 | 2019-02-07 | Bristol-Myers Squibb Company | INDOLE COMPOUNDS SUBSTITUTED WITH [1,2,4] TRIAZOLO [4,3-A] PYRIDINYL |
| WO2019099336A1 (en) | 2017-11-14 | 2019-05-23 | Bristol-Myers Squibb Company | Substituted indole compounds |
| SG11202005513TA (en) | 2017-12-15 | 2020-07-29 | Bristol Myers Squibb Co | Substituted indole ether compounds |
| US10544143B2 (en) | 2017-12-18 | 2020-01-28 | Bristol-Myers Squibb Company | 4-azaindole compounds |
| EA202091483A1 (ru) | 2017-12-19 | 2020-10-28 | Бристол-Маерс Сквибб Компани | Амидзамещенные индольные соединения, пригодные в качестве ингибиторов tlr |
| SG11202005696YA (en) | 2017-12-19 | 2020-07-29 | Bristol Myers Squibb Co | Substituted indole compounds useful as tlr inhibitors |
| AU2018390543A1 (en) | 2017-12-19 | 2020-08-06 | Bristol-Myers Squibb Company | 6-azaindole compounds |
| SG11202005733QA (en) | 2017-12-20 | 2020-07-29 | Bristol Myers Squibb Co | Diazaindole compounds |
| US11420958B2 (en) | 2017-12-20 | 2022-08-23 | Bristol-Myers Squibb Company | Aryl and heteroaryl substituted indole compounds |
| SG11202005694RA (en) | 2017-12-20 | 2020-07-29 | Bristol Myers Squibb Co | Amino indole compounds useful as tlr inhibitors |
| US20210403468A1 (en) | 2018-10-24 | 2021-12-30 | Bristol-Myers Squibb Company | Substituted indole and indazole compounds |
-
2017
- 2017-06-27 US US15/635,055 patent/US10071079B2/en not_active Ceased
- 2017-06-28 SI SI201730890T patent/SI3478682T1/sl unknown
- 2017-06-28 EA EA201990048A patent/EA037530B1/ru not_active IP Right Cessation
- 2017-06-28 KR KR1020197002353A patent/KR102473482B1/ko active IP Right Grant
- 2017-06-28 HU HUE17737442A patent/HUE056091T2/hu unknown
- 2017-06-28 EP EP17737442.8A patent/EP3478682B1/en active Active
- 2017-06-28 JP JP2018568837A patent/JP6995067B6/ja active Active
- 2017-06-28 AU AU2017287902A patent/AU2017287902B2/en active Active
- 2017-06-28 SG SG11201811590RA patent/SG11201811590RA/en unknown
- 2017-06-28 RS RS20211090A patent/RS62292B1/sr unknown
- 2017-06-28 CA CA3029620A patent/CA3029620A1/en active Pending
- 2017-06-28 CN CN201780052726.1A patent/CN109641895B/zh active Active
- 2017-06-28 PL PL17737442T patent/PL3478682T3/pl unknown
- 2017-06-28 AR ARP170101788A patent/AR108905A1/es unknown
- 2017-06-28 TW TW106121570A patent/TWI636053B/zh active
- 2017-06-28 ES ES17737442T patent/ES2886964T3/es active Active
- 2017-06-28 PE PE2018003329A patent/PE20190324A1/es unknown
- 2017-06-28 UY UY0001037310A patent/UY37310A/es unknown
- 2017-06-28 BR BR112018077119-8A patent/BR112018077119A2/pt unknown
- 2017-06-28 DK DK17737442.8T patent/DK3478682T3/da active
- 2017-06-28 PT PT177374428T patent/PT3478682T/pt unknown
- 2017-06-28 LT LTEPPCT/US2017/039633T patent/LT3478682T/lt unknown
- 2017-06-28 MY MYPI2018002975A patent/MY196474A/en unknown
- 2017-06-28 MX MX2018015422A patent/MX2018015422A/es active IP Right Grant
- 2017-06-28 WO PCT/US2017/039633 patent/WO2018005586A1/en unknown
-
2018
- 2018-07-23 US US16/042,116 patent/US10478424B2/en not_active Ceased
- 2018-12-25 IL IL263961A patent/IL263961B/en active IP Right Grant
- 2018-12-27 CL CL2018003821A patent/CL2018003821A1/es unknown
-
2019
- 2019-01-24 CO CONC2019/0000686A patent/CO2019000686A2/es unknown
- 2019-01-28 ZA ZA2019/00571A patent/ZA201900571B/en unknown
- 2019-10-15 US US16/653,297 patent/US10912766B2/en not_active Ceased
-
2020
- 2020-12-07 US US17/113,495 patent/US11672780B2/en active Active
-
2021
- 2021-08-04 HR HRP20211261TT patent/HRP20211261T8/hr unknown
- 2021-09-15 CY CY20211100814T patent/CY1124514T1/el unknown
-
2022
- 2022-01-25 US US17/584,155 patent/USRE49893E1/en active Active
- 2022-01-25 US US17/584,147 patent/USRE49931E1/en active Active
- 2022-01-25 US US17/584,139 patent/USRE49880E1/en active Active
-
2023
- 2023-04-26 US US18/307,119 patent/US20230255941A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211261T8 (hr) | [1,2,4]triazolo[1,5-a]piridinil supstituirani spojevi indola | |
| IL277576A (en) | Mutated pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | |
| IL265918A (en) | Pyrazolo [1,5– A] compounds Pyridine is converted as RET kinase inhibitors | |
| HK1258905A1 (zh) | 作為ret激酶抑制劑的取代的吡唑並[1，5-a]吡啶化合物 | |
| HK1258157A1 (zh) | 作為jak抑制劑的吡唑並[1，5-a]吡嗪-4-基衍生物 | |
| IL262673A (en) | Pyrazolo[1,5-a]pyrimidine compound | |
| IL290419B (en) | Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta |